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Summary
Background The prevalence of hepatitis E virus (HEV) genotype 3 infections in the English population (including 
blood donors) is unknown, but is probably widespread, and the virus has been detected in pooled plasma products. 
HEV-infected donors have been retrospectively identiﬁ ed through investigation of reported cases of possible 
transfusion-transmitted hepatitis E. The frequency of HEV transmission by transfusion and its outcome remains 
unknown. We report the prevalence of HEV RNA in blood donations, the transmission of the virus through a range 
of blood components, and describe the resulting morbidity in the recipients.
Methods From Oct 8, 2012, to Sept 30, 2013, 225 000 blood donations that were collected in southeast England were 
screened retrospectively for HEV RNA. Donations containing HEV were characterised by use of serology and genomic 
phylogeny. Recipients, who received any blood components from these donations, were identiﬁ ed and the outcome of 
exposure was ascertained.
Findings 79 donors were viraemic with genotype 3 HEV, giving an RNA prevalence of one in 2848. Most viraemic 
donors were seronegative at the time of donation. The 79 donations had been used to prepare 129 blood components, 
62 of which had been transfused before identiﬁ cation of the infected donation. Follow-up of 43 recipients showed 
18 (42%) had evidence of infection. Absence of detectable antibody and high viral load in the donation rendered 
infection more likely. Recipient immunosuppression delayed or prevented seroconversion and extended the duration 
of viraemia. Three recipients cleared longstanding infection after intervention with ribavirin or alteration in 
immunosuppressive therapy. Ten recipients developed prolonged or persistent infection. Transaminitis was common, 
but short-term morbidity was rare; only one recipient developed apparent but clinically mild post-transfusion hepatitis.
Interpretation Our ﬁ ndings suggest that HEV genotype 3 infections are widespread in the English population and 
in blood donors. Transfusion-transmitted infections rarely caused acute morbidity, but in some immunosuppressed 
patients became persistent. Although at present blood donations are not screened, an agreed policy is needed for 
the identiﬁ cation of patients with persistent HEV infection, irrespective of origin, so that they can be oﬀ ered 
antiviral therapy.
Funding Public Health England and National Health Service Blood and Transplant.
Copyright © Hewitt et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Hepatitis E was ﬁ rst recognised as a clinical disease in 
1978 as an outbreak of epidemic non-A, non-B hepatitis in 
Kashmir.1 In 1990, faecal extracts from cases in a Russian 
military camp were shown to be infectious orally in people 
and domestic pigs,2,3 with the infective agent hepatitis E 
virus (HEV) being partly sequenced the same year.4 There 
are four HEV genotypes—1 and 2 (human viruses), and 
3 and 4 (animal viruses) that infect human beings 
zoonotically. The results of a recent population-based 
seroprevalence study in England and Wales suggested that 
the prevalence of infection is more common than would 
be expected from an imported infection and that 25% of 
adults in the sixth and seventh decades of life are 
seropositive.5
In the UK, the numbers of cases of hepatitis E have 
increased every year since 20106 and this increase is 
associated with the emergence of a viral phylotype not 
previously seen. HEV is now the most common 
infective cause of acute enterically transmitted viral 
hepatitis and is detected in people who have not 
travelled outside the UK.7 The association between 
hepatitis E and con sumption of processed pork 
products makes hepatitis E a likely zoonosis in the UK8 
and other countries where viral sequencing has 
implicated food containing animal products from pigs,9 
boar,10 and deer.11
The ﬁ rst transmission in the UK of HEV from a blood 
component reported in 200612 was identiﬁ ed retro-
spectively in the recipients of blood components from a 
donor diagnosed with hepatitis E 24 days after donation. 
Post-transfusion hepatitis E seems unusual and since 
the ﬁ rst report eight post-transfusion HEV enquiries 
(two in 2013, ﬁ ve in 2012, and one in 2011) have been 
notiﬁ ed to the National Health Service Blood and 
Transplant (NHSBT). Only the two most recent cases 
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were conﬁ rmed to be linked to components from an 
infected donor. HEV RNA in UK plasma pools13,14 and 
serological evidence of recent HEV infection in donors15 
have also been documented, indicating a turnover of 
HEV in donors, but neither ﬁ nding provides a measure 
of the prevalence of viraemia. Intercurrent immuno-
suppression, common in component recipients, can 
delay viral clearance and lead to viral persistence in 
patients with solid organ transplant16 and HIV 
infection.17,18 These ﬁ ndings have raised the question of 
whether the hazard from HEV infection in donors 
ought to be deﬁ ned. We report here the prevalence of 
HEV RNA in blood donors, the transmission of HEV by 
a range of components, and we describe the resulting 
morbidity in recipients.
Methods
This study and related protocols were presented to the 
London Bridge Research Ethics Committee (reference 
12/LO/0987) and approval was received in September, 2012. 
An overarching data monitoring committee maintained 
an independent continuous review of the progress of the 
study. A study steering group, reporting to the data 
monitoring committee, reviewed all aspects of the study 
on a weekly basis. Identiﬁ cation and clinical follow-up of 
exposed recipients were coordinated by the NHSBT in 
accordance with existing protocols for the discharge of the 
duty of care to recipients of components carrying 
previously unidentiﬁ ed risks.
From Oct 8, 2012, to Sept 30, 2013, plasma samples 
from individual donations collected in the South East 
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Figure 1: Phylogenetic tree based on partial of open reading frame 2 nucleotide sequences from cases of HEV infection
The genotype 3 sequences are from acute hepatitis E cases diagnosed in England and Wales, UK, during the study period and are shown as unlabelled branches. 
Sequences from 54 HEV-infected blood donors are shown as blue dots and 12 HEV-infected recipients are shown as red dots. Accession numbers for reference 
sequences are given. HEV=hepatitis E virus.
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of England from consenting donors were dispatched 
from NHSBT Filton, Bristol, to NHSBT Colindale, 
London, UK, where minipools of 24 donations, or 
fewer if a full 24 set was not available at the time of 
pooling, were assembled and extracted on the 
QiaSymphony (Qiagen, Crawley, UK; virus-speciﬁ c 
cell-free protocol). At any point in time, staﬀ  and 
equipment limitations determined whether all 
sequential donations were taken for pooling or 
discarded. 9382 minipools were screened for HEV 
RNA during the study. HEV RNA was detected with 
an internally controlled RT-PCR19 (detection limit 
22 IU/mL). Brieﬂ y, extracted nucleic acid in 10 μL was 
reverse transcribed in 25 μL with Quantitect Probe 
rt-pcr (Qiagen, Crawley, UK) and then ampliﬁ ed 
through 45 cycles. Sample reactivity was ascribed an 
RNA value in IU/mL by comparison with a standard 
curve of serial log10 dilutions in normal human plasma 
of a high titre sample of known potency in WHO 
international units. Reactive pools were resolved to 
individual donations that were then subjected to HEV 
RNA detection, quantiﬁ cation, phylogeny, and serology. 
Plasma RNA was ampliﬁ ed, sequenced, and subjected 
to phylogenetic analysis across part of the open reading 
frame 2 as previously described.5
HEV antibody was detected with the Wantai IgM and 
IgG detection assays (Fortress Diagnostics, Antrim, 
Northern Ireland, UK) in accordance with the manufac-
turer’s instructions.
Unused blood components remaining in the NHSBT 
inventory were discarded and those already issued were 
recalled. A standard look back (ie, check) was initiated 
for all transfused components. The involved hospital 
trans fusion team was asked to identify the recipient and 
the clinical team providing patient care. The clinical 
team (or family doctor if the recipient had been 
discharged) was advised of the possible exposure to 
HEV and sent information about HEV and a suggested 
recipient follow-up plan.
Through the attending clinician, clinical information 
on all of the recipients was sought. Where possible, 
blood samples were collected during the follow-up. 
Negative serology at 16 weeks post-transfusion and an 
absence of HEV RNA at any stage indicated the lack of 
transmission. The detection of plasma RNA at any stage 
or seroconversion or serological markers of recent 
infection indicated transmission. Any recipient with 
viraemia was monitored until HEV RNA clearance and 
the development of both IgG and IgM.
Role of the funding source
This study was jointly funded by Public Health England 
and the NHSBT. Pooling was done on NHSBT premises. 
Serology, molecular testing, and phylogenetic analysis 
were done on Public Health England premises. Donor 
records, including consent for testing, enrolment, and 
clinical data were maintained by the NHSBT. The 
corresponding author had full access to all the data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
9382 minipools, comprising 225 000 individual donations, 
were screened and 79 donations containing HEV RNA 
were identiﬁ ed, giving a prevalence of about one in 
2848 donations (0·04%). 56 (71%) donors were sero neg-
ative (negative for anti-HEV IgM and anti-HEV IgG). The 
median viral load was 3900 IU/mL (range 50 to 2·37 × 10⁶) 
and was 0·5 log10 higher in index donations that were 
antibody negative. 54 (68%) of 79 donor samples could be 
genotyped and all had a genotype 3 virus (ﬁ gure 1).
129 components were manufactured from 79 donations 
(table 1). Red cells comprised the largest number 
(71 [55%]) followed by platelets (39 [30%]), but, because 
of discard or recall, only 62 (48%) components were 
given as transfusions to 60 recipients: one patient 
received two aliquots of an apheresis platelet donation, 
and another received two separate HEV-containing 
components (table 1). Platelets were the most commonly 
transfused virus-containing blood component (table 1).
Of the 60 patients given blood components from 
HEV-infected donors, one declined investigation. 
16 patients were not available for follow-up: nine died 
soon after transfusion and before follow-up, ﬁ ve were 
terminally ill or incapacitated and therefore the initiation 
of HEV monitoring was thought to be inappropriate, and 
Blood components associated 
with HEV-viraemic donation
Blood components 
recalled or discarded
Blood components 
transfused
Red blood cells 71 48 (68%) 23 (32%)
Pooled platelets 15 3 (20%) 12 (80%)
Apheresis platelets 24 1 (4%) 23 (96%)
Fresh frozen plasma 12 9 (75%) 3 (25%)
Cryoprecipitate 6 6 (100%) 0
Pooled granulocytes 1 0 1 (100%)
Total 129 67 (52%) 62 (48%)
Data are number or number (%).
Table 1: Blood components associated with viraemic donations
Recipients of blood 
components
Infected 
recipients
Uninfected 
recipients
Red blood cells 16 4 (25%) 12 (75%)
Pooled platelets 10 4 (40%) 6 (60%)
Apheresis platelets 14 7 (50%) 7 (50%)
Fresh frozen plasma 2 2 (100%) 0
Pooled granulocytes 1 1 (100%) 0
Total 43 18 (42%) 25 (58%)
Data are number or number (%).
Table 2: Association between transfused blood components and 
transmission of hepatitis E virus in 43 of 60 exposed patients in whom 
follow-up was possible
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two had returned to their country of origin. In no case 
did the clinical team judge that HEV had contributed to 
any illness or to death. Therefore, 43 patients were 
followed up (table 2).
Six patients (1–3, 6, 7, and 10) had serological markers of 
the recent development of antibody (seroconversion) 
when ﬁ rst tested at a median of 6 weeks (range 3–14 weeks) 
after transfusion (table 3). High concentrations of anti-
HEV IgG (sample/cutoﬀ  [S/CO] >20) were detected in all 
samples, IgM was detected in one sample (S/CO 1·2), and 
borderline IgM (S/CO 0·7–0·9) was detected in three 
samples. A further 12 recipients were viraemic at one or 
more timepoints in the post-transfusion period (table 3). 
Taking both groups together, the overall transmission rate 
was 42% (18 of 43 exposed patients), supported by the 
ﬁ nding of sequences in each of the 12 viraemic recipients 
that were identical to sequences from the involved donors 
(ﬁ gure 1). 25 recipients were judged to not have been 
infected, 16 of whom had no serological evidence of HEV 
infection at 16 weeks after transfusion and nine who were 
both seronegative and non-viraemic at 8 weeks or longer 
after transfusion.
The components associated with transmission of 
HEV to recipients are shown in table 2; red blood cells 
seemed to be the component least likely to transmit 
infection. HEV antibody was detected in four (22%) of 
18 donations associated with virus transmission and 
in 13 (52%) of 25 donations not associated with 
Primary 
diagnosis
Inferred 
immune 
suppression
Weeks to RNA 
positivity
Weeks to ﬁ rst 
detection of 
antibody
Duration of 
infection (weeks)*
Viral clearance Alanine 
aminotransferase 
(IU/ml)
Comment
Patients 1–8
Patient 1 Cardiac surgery None Marker not 
detected
8 NA Yes Not raised No illness
Patient 2 Cardiac surgery None Marker not 
detected
14 NA Yes No information No illness
Patient 3 Gastrointestinal 
bleeding
None Marker not 
detected
6 NA Yes Not raised No illness
Patient 4 Cardiac surgery None 5 5 7 Yes 375, week 7 Mild jaundice
Patient 5 Sepsis None 2 10 10 Yes 42, week 2 No information
Patient 6 Myelodysplastic 
syndrome
Mild Marker not 
detected
6 NA Yes Not elevated No illness
Patient 7 Myelodysplastic 
syndrome
Mild Marker not 
detected
3 NA Yes No information No information
Patient 8 Myelodysplastic 
syndrome
Mild 14 28 28 Yes 101, week 21 No information
Median for patients 1–8 ·· ·· 5 7 10 ·· ·· ··
Patients 9–14
Patient 9 Aplastic anaemia Moderate 8 Marker not detected >12 No† 43, week 4 Sepsis death†
Patient 10 Metastatic cancer Moderate Marker not 
detected
6 NA Yes No information No information
Patient 11 Aplastic anaemia Moderate 4 10 >10 No† 200, week 7 Cardiac death†
Patient 12 Acute renal failure Moderate 3 11 11 Yes 148, week 9 Steroid reduction
Patient 13 Non-Hodgkin 
lymphoma
Moderate 13 13 >43 No No information No information
Patient 14 Acute myeloid 
leukaemia
Moderate 12 21 25 Yes 1380, week 20 No information
Median for patients 9–14 ·· ·· 8 11 18 ·· ·· ··
Patients 15–18
Patient 15 Acute myeloid 
leukaemia
High 17 38 >40 No Not elevated Deceased
Patient 16 Acute myeloid 
leukaemia
High 7 Marker not detected 16 Yes Not elevated 11 weeks of 
Ribavirin
Patient 17 Failed transplant High 7 Marker not detected >10 No† 295‡, week 7 Sepsis death†
Patient 18 Multi organ 
transplant
High 11 37 44 Yes 40, week 22 Reduction of drug 
dose
Median for patients 15–18 ·· ·· 9 37·5 30 ·· ·· ··
Data are number, unless otherwise indicated. Median values are calculated from the numerate values in the table. NA=not applicable. *Period from transfusion to last detection of hepatitis E virus RNA; marked > 
when still viraemic after the end of follow-up. †Recipient died during follow-up, so relevant data excluded from numerical analysis. ‡Transaminitis thought to be secondary to abdominal sepsis and haematoma.
 Table 3: Outcome in 18 recipients infected by transfusion of a blood component from a viraemic donor, ranked by immunosuppression
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transmission. The antibody levels were much lower in 
the four donations that resulted in transmission than in 
the 13 that did not (ﬁ gure 2A). The HEV viral load was 
about 1·5 log10 higher in the donations that transmitted 
than in those that did not (ﬁ gure 2B).
Follow-up of the infected recipients showed a varied 
response to infection, reﬂ ecting their overall clinical state 
and inferred degree of immunosuppression. The median 
times for seroconversion and duration of infection 
increased in patients as the degree of immunosuppression 
increased (table 3). Eight patients (1–8) were deemed to be 
immunocompetent or only mildly immunosuppressed 
(table 3). Five patients cleared their infection without 
having detectable viraemia, the other three recipients 
cleared their RNA in a median of 10 weeks (table 3). 
Six patients (9–14) with varying degrees of moderate 
immunosuppression had a longer median time of 11 weeks 
to seroconversion and a median duration of viraemia of 
18 weeks (table 3). Four patients (15–18) were judged to be 
heavily immunosuppressed. In these patients, sero-
conversion was either very delayed (week 38 for patient 15 
and week 37 for patient 18) or was not detected.
In three viraemic recipients, one moderately (patient 12) 
and two severely immunosuppressed (patients 16 and 18), 
an elective decision was made to induce viral clearance. 
In patient 12, steroid dose reduction and withdrawal of 
additional immunosuppressive drugs 9 weeks after 
transfusion led to seroconversion and viral clearance 
over 3 weeks. In patient 18, changes in immuno-
suppressive therapy coincided with the onset of 
seroconversion at 37 weeks and subsequent viral 
clearance from both stool and plasma. In patient 16, 
2 weeks of ribavirin was given between cycles of 
chemotherapy at 12 weeks after transfusion and led to a 
1000 times reduction in HEV RNA concentrations but 
not to clearance. Further ribavirin treatment starting at 
19 weeks after transfusion led to viral clearance in the 
absence of a detectable antibody response.
Clinical hepatitis was reported in only one recipient 
(patient 4), whose indication for transfusion was a cardiac 
surgical procedure (table 3). 5 weeks after transfusion, 
the patient consulted with the family doctor and was 
conﬁ rmed to have hepatitis, associated with HEV 
seroconversion. Four other recipients (patients 8, 11, 12, 
and 14) had asymptomatic transaminitis coincident with 
seroconversion, which was triggered in patient 12 by a 
change in therapy. Transaminitis was marked in 
patient 14 in whom plasma alkaline phosphatase was also 
elevated for 1 week before the ﬁ rst development of 
anti-HEV antibodies. No infected patient was reported to 
have neurological disease.
Discussion
The prevalence of blood donations containing HEV RNA 
was higher than anticipated in the planning of the 
project. When projected across the country, and 
allowances are made for the duration of a detectable 
viraemia for 8 weeks, a prevalence of one in 2848 
indicates that about 80 000–100 000 acute HEV infections 
are likely to have occurred in England during the year of 
the study. This is close to the modelled estimate20 and 
shows a truly sizeable zoonosis, including both group 1 
and group 2 viruses of genotype 3 HEV,7 which was also 
transmitted to the donors identiﬁ ed in this study 
(ﬁ gure 1). Similar prevalences of viraemia have been 
reported in Sweden and Germany,21–23 suggesting that 
this zoonosis is also widespread across the European 
continent, further supported by a recently reported case 
of post-transfusion HEV in France (panel).24
The inevitable delay between donation and the 
identiﬁ cation of a viraemic donor meant that when recall 
of components was started, a high proportion of the short 
shelf-life components had already been transfused and 
most of the recalled units were inevitably of the longer 
shelf-life red cell and frozen components. This might 
have altered the proﬁ le of recipients towards those who 
were immunosuppressed and requiring platelet support.
Two linked variables in the donor plasma that were 
associated with transmission were the anti-HEV status of 
the donation and the level of virus in the plasma 
(ﬁ gure 2A, 2B). Overall, donations containing antibody 
were less likely to transmit and, when they did, there was a 
trend for lower levels of anti-HEV to be associated with 
transmission. Donations associated with transmission had 
signiﬁ cantly higher levels of plasma RNA (p<0·0001) than 
did those not associated with transmission, but overall 
viral RNA levels were ten times lower in viraemic donors 
than in the plasma of patients presenting with acute 
clinical hepatitis E (median 6·2 × 10⁴ IU/ml, range 20 to 
Figure 2: Data spread plot of HEV IgM and IgG antibody levels in donors whose components transmitted HEV 
compared with those that did not (A) and HEV RNA levels in donors whose components transmitted HEV 
compared with those that did not (B)
In (B), the bars indicate median viral load values for donations that were or were not associated with HEV infections 
(4·53 IU/mL [range 2·61–5·41] vs 2·57 IU/mL [1·70–5·49], p<0·0001). S/CO=sample/cutoﬀ .
A B
IgM IgG IgGIgM
S/
CO
 
HE
V 
RN
A 
vi
ra
l lo
ad
 lo
g 1
0 (
IU
/m
L)
0
4
2
6
0
5
10
15
20
25
Donations associated 
with HEV 
infections (n=18)
Donations not
associated with
HEV infections (n=25)Donations associated 
with HEV 
infections (n=4)
Donations not
associated with
HEV infections (n=13)
Articles
www.thelancet.com   Vol 384   November 15, 2014 1771
4·2 × 10⁷; unpublished data). In this study it was not 
possible to ascertain the serological status of the recipient 
before transfusion because of the unavailability of samples.
The numbers of components in each category were 
insuﬃ  cient for a robust attribution of transmissibility, 
though there is clearly a trend for those components that 
contain larger plasma volumes, principally fresh frozen 
plasma and platelet components, to transmit more 
readily. Despite this, in some instances apparently 
susceptible individuals who were challenged with 
components prepared from donors with high-level HEV 
viraemia did not become infected, raising the question of 
whether some people are innately resistant to infection 
or whether coincidental administration of antibody-
containing components from other donors might also 
have mitigated the risk of infection.
Table 3 shows that the immunological integrity of the 
host materially alters the time course of the post-
transfusion infection. Increasing immunosuppression 
prolongs viraemia and delays seroconversion. Although 
eight of 12 viraemic recipients underwent serocon-
version, coinciding in some with a biochemical 
transaminitis, seroconversion does not necessarily 
bring about clearance and can still be followed by long-
term viraemia (patients 13 and 15). At the other end of this 
range, four heavily immuno suppressed patients either 
did not produce anti-HEV or had very delayed 
seroconversion and exhibited prolonged viraemia as 
described previously in recipients of solid organ 
transplants.16
What is of concern in this small series is that ten patients 
infected through transfused components seemed likely to 
be at the beginning of long-term persistence. Two patients 
(8 and 14) cleared viraemia spontaneously late after 
infection, four (9, 11, 15, and 17) remained viraemic at time 
of their deaths, and four (12, 13, 16, and 18) were at risk of 
chronic liver disease and requiring continued monitoring 
and possible inter vention. In three cases, the decision to 
attempt viral clearance was made. Indirect antiviral 
intervention with electively reduced immunosuppression 
led to seroconversion and viral clearance in two recipients 
(10 and 18). Direct antiviral intervention with ribavirin led 
to resolution of the infection without seroconversion in 
patient 16. The fourth patient (13) remains the only 
persistently infected recipient a year after transfusion.
Our ﬁ ndings conﬁ rm the potential danger of 
transfusion-transmitted HEV in the transplant and 
haemoncology settings but also the susceptibility of this 
persistent infection to immune clearance. Persistent 
infection might be more of a hazard for recipients of solid 
organ transplant in whom the immunosuppression is 
unremitting than for recipients of stem cell trans-
plantation in which immune recovery might be expected. 
Based on the ﬁ nding of little acute morbidity, there is no 
indication to alter previously optimised treatment 
pathways for patients who have been exposed or infected 
with HEV. Two-thirds of patients are likely to clear 
infection spontaneously, and when long-term persistence 
develops intervention can be undertaken electively.25 
Immune recovery is the desired outcome in many 
haematological situations and this alone might well bring 
about viral clearance that might also be associated, like 
seroconversion, with an illness during viral clearance.26
Since HEV infection transmits through transfusion 
and the incidence of acute infection in donors from the 
southeast of England is high, about 1200 HEV-containing 
components are likely to be released for transfusion 
purposes each year in England. Most infections will not 
be identiﬁ able through any acute illness in the immediate 
post-transfusion period but might present much later at 
the time of immune reconstitution or as a manifestation 
of long-term chronic liver disease, especially in solid 
organ transplants when an association with transfusion 
might not be made. One way of mitigating unfavourable 
outcomes would be to introduce routine yearly screening 
for persistent HEV infection in all transplant patients 
with an option to treat those who are chronically infected 
independent of the route of infection.
Setting aside this option, what would be a proportionate 
response to this zoonosis? Is it possible to deal with the 
source of infection that is likely to be foods containing 
pork,8 perhaps advising patients at risk to modify their 
diet as is done for listeria? A societal change reverting to 
the old principle of extended cooking of pork would not 
ﬁ t with the tendency to consume it lightly cooked now 
that trichinosis is no longer a perceived hazard.27 
Addressing animal husbandry and determining how to 
Panel: Research in context
Systematic review
We searched MedLine for articles published in the 7 years up 
to December, 2013, on the topic of HEV and blood safety. We 
used a range of keywords including “hepatitis E”, “HEV”, 
“blood safety”, “transmission”, “blood donors”, and 
“recipients”. In the past 10 years hepatitis E virus (HEV) has 
been increasingly recognised as a zoonotic infection in high-
income countries where it was previously thought to be an 
imported infection. Current infection in blood donors and a 
small number of post-transfusion cases from some countries 
indicate a potential for transmission by transfusion. No 
systematic analysis of transmission rates and clinical eﬀ ect of 
transfusion-transmitted HEV exists in published literature.
Interpretation
We have deﬁ ned the prevalence of viraemic donors and 
transmission to recipients. Spontaneous clearance without 
clinical disease was common, despite delayed seroconversion, 
and resulting acute illness was rare. Our data are from the ﬁ rst 
reported systematic study of HEV transmission from donors 
infected by an extensive but largely non-apparent zoonosis in 
England. On a clinical basis alone, the resulting minimal 
burden of disease does not signal a pressing need for 
donation screening at this time.
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control HEV in pig herds remains a possibility, although 
an easily transmissible enteric agent like HEV28 will be 
more diﬃ  cult to control than trichinella. Alternatively, 
screening of blood donations, at substantial cost, on the 
basis of reducing the risk of long-term infection, would 
remove the bulk of the transfusion hazard but still allow 
the dietary risk to transplant patients; this issue was 
addressed in Toulouse, France, by the removal of the 
ﬁ gatelu liver sausage from the hospital diet.9 
Nevertheless, every donor exposure in England and 
Wales will increase the likelihood of recipient infection 
by one in 3000, and if a recipient in 1 year of treatment 
were to be exposed to components from 20 donors the 
accumulated yearly risk from transfusion would be one 
in 150 compared with a dietary risk of one in 500–1000, 
modelled on the yearly seroconversion rate of 0·1–0·2%. 
Our experience in this study, however, indicates that the 
burden of harm engendered by HEV acquisition through 
transfusion is very slight and from a clinical perspective 
alone there seems no pressing need to move rapidly with 
the introduction of donation screening. The broader 
issues of HEV and blood safety, including the need for 
donation screening,29 will be addressed in the UK later 
this summer after the recent commissioning of a 
short-life expert committee of the UK Departments of 
Health Advisory Committee on the Safety of Blood, 
Tissues and Organs to consider these matters within the 
context of a ﬁ nancially constrained health service.
The magnitude of the current zoonosis in Europe is 
shown by both more cases of hepatitis E being reported 
for England in 2012 than in 2011,7 and an increase in 
prevalence of HEV antibody in young Dutch blood 
donors (Zaaijer H, Sanquin Blood Supply Foundation, 
personal communication). It should be borne in mind 
that HEV disease in England and Wales shows 
considerable temporal variation, and though the 
magnitude of the risk now possibly justiﬁ es intervention30 
it is unlikely that the high frequency of acute infection 
will be maintained indeﬁ nitely; this provides another 
complication in the decision of an appropriate response 
to this interesting and rather unexpected transfusion-
associated infection in the UK. 
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